<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2537">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04603924</url>
  </required_header>
  <id_info>
    <org_study_id>ANA001-001</org_study_id>
    <nct_id>NCT04603924</nct_id>
  </id_info>
  <brief_title>Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients</brief_title>
  <official_title>A Phase 2/3 Randomized and Placebo-Controlled Study of ANA001 in Moderate and Severe COVID-19 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ANA Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ANA Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study of ANA001 in Moderate and Severe COVID-19 Patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 2 part, Phase 2/3 multi-center, double blinded, placebo-controlled study to assess&#xD;
      the safety, tolerability, and efficacy of oral niclosamide (ANA001) in moderate and severe&#xD;
      hospitalized COVID-19 patients compared to placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 7, 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of ANA001 as measured by the incidence of treatment emergent adverse events (TEAE's) (Part 1 and Part 2)</measure>
    <time_frame>Randomization to Day 28</time_frame>
    <description>Incidence of treatment emergent adverse events (TEAE's)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy as measured by median time to hospital discharge (Part 2)</measure>
    <time_frame>Randomization to Day 60</time_frame>
    <description>Median time to hospital discharge</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy as measured by median time to hospital discharge (Part 1)</measure>
    <time_frame>Randomization to Day 60</time_frame>
    <description>Median time to hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of ANA001 as measured by plasma concentrations (Part 1)</measure>
    <time_frame>Day 1, 2, 3 or 4</time_frame>
    <description>Plasma concentrations of ANA001</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of ANA001 as measured by mean change from baseline in the National Early Warning Score (NEWS 2) (Part 2)</measure>
    <time_frame>Day 15</time_frame>
    <description>Mean change from baseline in National Early Warning Score (NEWS 2) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of ANA001 as measured by mean number of days on rescue therapy (Part 2)</measure>
    <time_frame>Within 15 days after enrollment</time_frame>
    <description>Mean number of days on rescue therapy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">436</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>ANA001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in the ANA001 treatment arm will receive 1,000 mg (4 capsules; 250 mg each) by mouth twice per day for 7 consecutive days with a meal. If the participant requires mechanical ventilation over the course of the study, ANA001 may be administered via nasogastric (NG), percutaneous endoscopic gastrostomy (PEG) or orogastric (OG) tube and, if possible, should be administered with a scheduled nasogastric (NG) or orogastric (OG) feeding.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects in the comparator arm will receive matching placebo (hydroxypropylmethylcellulose (HPMC)) (4 capsules, by mouth twice a day) for the 7-day treatment duration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niclosamide</intervention_name>
    <description>Niclosamide is an antihelmintic with in-vitro antiviral activity</description>
    <arm_group_label>ANA001</arm_group_label>
    <other_name>ANA001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching hydroxypropylmethylcellulose HPMC capsules with no active ingredients</description>
    <arm_group_label>Matching Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Provide written informed consent prior to performing study procedures&#xD;
&#xD;
          2. Hospitalized.&#xD;
&#xD;
          3. Male or female ≥18 years of age&#xD;
&#xD;
          4. Positive for severe acute respiratory syndrome coronavirus 2&#xD;
&#xD;
          5. Presence of symptoms of lower respiratory tract infection (LRTI) including at least 1&#xD;
             of the following: fever, cough, sore throat, malaise, headache, muscle pain, or more&#xD;
             significant lower respiratory tract symptoms, including shortness of breath&#xD;
&#xD;
          6. At least 1 of the following: respiratory rate (RR) ≥20 breaths per minute, room air&#xD;
             oxygen saturation (SpO2) &lt;98%, requirement for supplemental oxygen, heart rate (HR)&#xD;
             ≥90 beats per minute, or temperature &gt;38.3°C&#xD;
&#xD;
          7. Women of childbearing potential must agree to abstinent or use at least 1 form of&#xD;
             contraception not including hormonal contraception from the day of screening through&#xD;
             Day 30&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
        1. Hospitalized but no longer requires ongoing inpatient care (i.e., discharge is&#xD;
        anticipated in ≤24 hours) 2. Patient is not anticipated to survive &gt;48 hours OR is under&#xD;
        palliative care 2. Respiration Rate ≥30 breaths per minute, Heart Rate ≥125 beats per&#xD;
        minute, or Oxygen Saturation (SpO2) ≤93% on ≤ 2 L/min nasal cannula oxygen 3. Evidence of&#xD;
        critical illness, defined by at least 1 of the following:&#xD;
&#xD;
        ● Respiratory failure requiring at least 1 of the following:&#xD;
&#xD;
          1. Endotracheal intubation and mechanical ventilation, oxygen delivered by high flow&#xD;
             nasal cannula&#xD;
&#xD;
          2. Noninvasive positive pressure ventilation (NIPVV), OR&#xD;
&#xD;
          3. Extracorporeal membrane oxygenation (ECMO) or clinical diagnosis of respiratory&#xD;
             failure&#xD;
&#xD;
               -  Shock (defined by systolic blood pressure (BP) &lt;90 mm Hg, or diastolic blood&#xD;
                  pressure (BP) &lt;60 mm Hg or requiring vasopressors), OR&#xD;
&#xD;
               -  Multi-organ dysfunction/failure 4. Severe central nervous system (CNS) conditions&#xD;
                  5. Chronic kidney disease requiring dialysis 6. Known allergy to the study drug&#xD;
                  or salicylate containing medications. 7. Suspected and/or confirmed pregnancy or&#xD;
                  breastfeeding 8. Current or planned participation in any other clinical trial of&#xD;
                  a treatment being developed under a US investigational new drug (IND) or&#xD;
                  emergency use authorization (EUA).&#xD;
&#xD;
                  9. Patients receiving chemotherapeutic agents and/or immunomodulators (including&#xD;
                  monoclonal antibodies (Mabs) or plasma transfusions) for chronic disease&#xD;
                  conditions.&#xD;
&#xD;
                  10. Patients who receive the severe acute respiratory syndrome coronavirus 2&#xD;
                  vaccine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Doug Rank, MD</last_name>
    <role>Study Director</role>
    <affiliation>ANA Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Akash Bakshi</last_name>
    <phone>1 650-263-1270</phone>
    <email>akash@anatherapeutics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrew Bartynski</last_name>
    <phone>1 650-263-1270</phone>
    <email>andrew@anatherapeutics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Helen Keller Hospital</name>
      <address>
        <city>Sheffield</city>
        <state>Alabama</state>
        <zip>35660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akash Bakshi</last_name>
      <email>clinicaltrialinfo@anatherapeutics.com</email>
    </contact>
    <contact_backup>
      <last_name>Andrew Bartynski</last_name>
      <phone>1650-263-1270</phone>
      <email>clinicaltrialinfo@anatherapeutics.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Baptist Health Research Institute</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akash Bakshi</last_name>
      <phone>650-263-1270</phone>
      <email>clinicaltrialinfo@anatherapeutics.com</email>
    </contact>
    <contact_backup>
      <last_name>Andrew Bartynski</last_name>
      <phone>1 650-263-1270</phone>
      <email>clinicaltrialinfo@anatherapeutics.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Therapeutic Concepts, PA</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akash Bakshi</last_name>
      <phone>650-263-1270</phone>
    </contact>
    <contact_backup>
      <last_name>Andrew Bartynski</last_name>
      <phone>1650-263-1270</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 20, 2020</study_first_submitted>
  <study_first_submitted_qc>October 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2020</study_first_posted>
  <last_update_submitted>January 22, 2021</last_update_submitted>
  <last_update_submitted_qc>January 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Corona Virus Disease (COVID-19)</keyword>
  <keyword>Niclosamide</keyword>
  <keyword>Antiviral</keyword>
  <keyword>Immunomodulator</keyword>
  <keyword>Oral Niclosamide</keyword>
  <keyword>Infection</keyword>
  <keyword>Acute Respiratory Distress Syndrome (ARDS)</keyword>
  <keyword>Cytokine dysregulation</keyword>
  <keyword>Virus</keyword>
  <keyword>Viral</keyword>
  <keyword>anthelmintic</keyword>
  <keyword>anti-inflammatory</keyword>
  <keyword>bronchodilator</keyword>
  <keyword>antineoplastic</keyword>
  <keyword>ANA001</keyword>
  <keyword>Moderate COVID-19</keyword>
  <keyword>ARDS</keyword>
  <keyword>Acute Respiratory Distress Syndrome</keyword>
  <keyword>Hospitalized COVID-19</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niclosamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

